Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 302 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Heart Failure, Preserved Ejection Fraction Clear all
Completed No phase listed Observational

Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data

NCT06914102
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
58,387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Nov 7, 2026, 10:38 AM EST
Recruiting Not applicable Interventional

Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

NCT05577819
View directory record Official record
Conditions
Transthyretin Amyloidosis, Heart Failure, Heart Failure, Diastolic, Amyloidosis
Interventions
99mTc-pyrophosphate Scintigraphy
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
65 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 7, 2026, 10:38 AM EST
Recruiting Phase 1 Interventional

Novel Approaches for Improving Vascular Function in Veterans With HFpEF

NCT06312748
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Inflammation
Interventions
L-Citrulline, Placebo for L-Citrulline, BH4, Placebo for BH4, Atorvastatin, Placebo for Atorvastatin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Nov 7, 2026, 10:38 AM EST
Completed Not applicable Interventional Results available

Exercise Intolerance in Elderly Patients With Diastolic Heart Failure

NCT00959660
View directory record Official record
Conditions
Heart Failure, Diastolic, Obesity
Interventions
Exercise, Dietary Intervention, Diet and exercise, Attention Control
Behavioral · Dietary Supplement · Other
Lead sponsor
Wake Forest University
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Nov 7, 2026, 10:38 AM EST
Recruiting Phase 4 Interventional

A Preliminary Study for INFORMED

NCT05585125
View directory record Official record
Conditions
Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Diseases
Interventions
Beta blocker
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 7, 2026, 10:38 AM EST
Terminated Not applicable Interventional

Patients With Heart Failure With Preserved Ejection Fraction Adherence to ASV Therapy (PEP ASV)

NCT04133350
View directory record Official record
Conditions
Sleep Disorder; Breathing-Related, Heart Failure
Interventions
Active Patient Engagement
Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Nov 7, 2026, 10:38 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction

NCT02980068
View directory record Official record
Conditions
Pulmonary; Hypertension, Heart Failure, Preserved Ejection Fraction
Interventions
15N Nitrate, 14N Nitrate
Drug
Lead sponsor
Gladwin, Mark, MD
Individual
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Nov 7, 2026, 10:38 AM EST
Completed Phase 2 Interventional Results available

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

NCT03541603
View directory record Official record
Conditions
Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
Interventions
Levosimendan, Matching Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Nov 7, 2026, 10:38 AM EST
Completed Phase 2Phase 3 Interventional

Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)

NCT04945707
View directory record Official record
Conditions
Iron-deficiency, Heart Failure With Preserved Ejection Fraction
Interventions
Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric], Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 7, 2026, 10:38 AM EST
Completed Not applicable Interventional

Exercise Training Effect in Patients With HF and PEF

NCT02696486
View directory record Official record
Conditions
Heart Failure
Interventions
Exercise Training
Behavioral
Lead sponsor
MultiCare Health System Research Institute
Other
Eligibility
55 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Nov 7, 2026, 10:38 AM EST
Terminated Not applicable Interventional

Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction

NCT00574756
View directory record Official record
Conditions
Ranolazine, Diastolic Heart Failure, Tissue Doppler Ultrasound, Echocardiography
Interventions
ranolazine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Nov 7, 2026, 10:38 AM EST
Terminated Phase 2 Interventional Results available

The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure

NCT01887353
View directory record Official record
Conditions
Atrial Fibrillation, Heart Failure
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jul 20, 2015 · Synced Nov 7, 2026, 10:38 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity

NCT07052539
View directory record Official record
Conditions
Chronic Kidney Disease, Heart Failure With Preserved Ejection Fraction (HFPEF), Obesity (Disorder)
Interventions
High protein and sodium meal
Other
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Nov 7, 2026, 10:38 AM EST
Completed Phase 3 Interventional Results available

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

NCT03066804
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
sacubitril/valsartan, Enalapril, Valsartan, Placebo to match sacubitril/valsartan, Placebo to match enalapril, Placebo to match valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
2,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
32
States / cities
Andalusia, Alabama • Mobile, Alabama • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Nov 7, 2026, 10:38 AM EST
Terminated Phase 2 Interventional Results available

A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT05592275
View directory record Official record
Conditions
Heart Failure, Heart Failure With Preserved Ejection Fraction
Interventions
LY3540378, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Tucson, Arizona • Covina, California • Northridge, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Nov 7, 2026, 10:38 AM EST
Recruiting Phase 2 Interventional

CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation

NCT06762964
View directory record Official record
Conditions
Fontan Circulation, Single Ventricle Heart Disease, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
Dapagliflozin tablet, Placebo Tablet
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 7, 2026, 10:38 AM EST
Completed Phase 2 Interventional Results available

Oral Nitrite for Older Heart Failure With Preserved Ejection Fraction

NCT02918552
View directory record Official record
Conditions
Heart Failure
Interventions
sodium nitrite, Control
Drug
Lead sponsor
Gladwin, Mark, MD
Individual
Eligibility
70 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Nov 7, 2026, 10:38 AM EST
Completed Not applicable Interventional

Balance, Aerobic Capacity, Mobility and Strength in Patients Hospitalized for Heart Failure (BAMS-HF) Program

NCT04281849
View directory record Official record
Conditions
Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure，Congestive, Heart Failure; With Decompensation, Heart Failure Acute, Heart Failure With Reduced Ejection Fraction
Interventions
BAMS-HF Program
Behavioral
Lead sponsor
VA Eastern Colorado Health Care System
Federal
Eligibility
55 Years to 100 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Nov 7, 2026, 10:38 AM EST
Completed Not applicable Interventional

Reverse HFpEF: Ketogenic Reversal of Heart Failure With Preserved Ejection Fraction Study

NCT04942548
View directory record Official record
Conditions
Heart Failure
Interventions
Ketogenic Diet
Other
Lead sponsor
National Jewish Health
Other
Eligibility
21 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Nov 7, 2026, 10:38 AM EST
Not yet recruiting Not applicable Interventional

Boston Medical Center Ultrasound Decongestion Study in Heart Failure

NCT07096726
View directory record Official record
Conditions
Congestive Heart Failure, Volume Overload
Interventions
Five-point ultrasound, Standard of care
Device · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Nov 7, 2026, 10:38 AM EST
Active, not recruiting Not applicable Interventional

Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study

NCT05136820
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions
Atrial Flow Regulator, Sham Comparator
Device
Lead sponsor
Occlutech International AB
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Phoenix, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Nov 7, 2026, 10:38 AM EST
Terminated Phase 3 Interventional Results available

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction

NCT03037580
View directory record Official record
Conditions
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions
Oral treprostinil, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Nov 7, 2026, 10:38 AM EST
Completed No phase listed Observational Accepts healthy volunteers

2 New Measurements Used to Describe the Filling Phase of the Left Ventricle (LV).

NCT04154878
View directory record Official record
Conditions
Diastolic Heart Failure, Left Ventricular Diastolic Dysfunction, Left Ventricular Diastolic Collapse
Interventions
Not listed
Lead sponsor
AdventHealth
Other
Eligibility
45 Years to 85 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Nov 7, 2026, 10:38 AM EST
Recruiting Phase 1 Interventional

Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction

NCT06061549
View directory record Official record
Conditions
Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction
Interventions
AAV1/SERCA2a
Biological
Lead sponsor
Sardocor Corp.
Industry
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Durham, North Carolina • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Nov 7, 2026, 10:38 AM EST